Optiscan Opens US FDA Review for InForm Digital Pathology Device
Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.
- 510(k) submission lodged for InForm digital pathology device
- Formal FDA review now begins, with no approval timetable disclosed
- Slide-free imaging targets a largely analogue pathology workflow
- Clinical studies and commercial readiness work will continue
- US clearance would be required for commercial distribution in cleared indications
Optiscan Imaging Ltd (ASX:OIL) has put its flagship InForm™ device in front of the US Food and Drug Administration, lodging a 510(k) submission that moves the technology beyond internal development and into formal regulatory review.
That is a meaningful step, but not the finish line. The submission is a prerequisite for potential US commercialisation; it is not FDA clearance. The agency will first assess whether the application can proceed, then review the device’s technical performance and supporting evidence. It may also request clarification or additional information before reaching a determination.
InForm Targets Slide-Free Pathology
InForm is designed to produce real-time digital microscopic images directly from freshly excised tissue or tissue fixed in preservatives commonly used in pathology laboratories. That sets it apart from digital pathology systems built primarily around scanning prepared glass slides, and gives Optiscan a chance to establish a different point in the clinical workflow rather than simply compete in the existing scanner market.
The opportunity is substantial on paper: Optiscan cites a US anatomic pathology market valued at approximately US$10.6 billion in 2025 and forecast to reach US$15.35 billion by 2030. Yet the company also acknowledges the trade-off. A new workflow will need clinical validation, integration into established practice and user acceptance before the device’s technical attributes translate into broad adoption.
Clinical Evidence Continues After Submission
The filing follows technical testing, clinical evidence gathering and regulatory documentation intended to support InForm’s safety, performance and substantial equivalence to an appropriate legally marketed predicate device. Optiscan says clinical studies will continue during the FDA review, expanding the evidence base rather than treating submission as the endpoint of the programme.
At the same time, the company plans to develop clinical reference sites, deepen engagement with pathology customers and institutions, and assess potential commercial partnerships. Those activities are intended to help shape future customer targeting, training, support and sales models, although the announcement provides no revenue forecast, launch date or expected clearance timing.
FDA Clearance Is the Next Value-Creating Gate
A successful 510(k) determination would allow InForm to be commercially distributed in the US for its cleared indications, marking the transition from regulatory and clinical development to market entry. Until then, the central question is whether the FDA accepts Optiscan’s equivalence case and finds the submitted technical and clinical package sufficient.
The company says the work has also strengthened internal capabilities across regulatory affairs, clinical development, quality systems, engineering, manufacturing and operations. That may matter beyond InForm, but the immediate test is narrower and more concrete: how the FDA responds to the submission, and whether the evidence supports the commercial workflow Optiscan is seeking to establish.
Bottom Line?
The submission removes a major development hurdle, but FDA clearance, defined indications and evidence of clinical adoption remain unresolved.
Questions in the middle?
- Will the FDA accept the submission without requesting substantial additional information?
- What indications and workflow claims could InForm receive if clearance is granted?
- Can Optiscan convert clinical reference sites into repeatable commercial adoption in US pathology?
